Pergamum's PXL-01 misses Phase II endpoint

Pergamum AB (Stockholm, Sweden) said topical PXL-01 missed the primary endpoint vs. placebo in a Phase II trial to prevent post-surgical adhesions in patients undergoing flexor tendon repair surgery. ...